BCR-ABL 測試市場：規模、份額、法規、按細分市場劃分的報銷、到 2033 年的預測

白血病是一組影響血液和骨髓的異質性癌症。 兩種常見的亞型是淋巴球白血病和髓細胞白血病，它們分別起源於淋巴球和粒細胞。 白血病可以快速進展（急性）或緩慢進展（慢性），是 20 歲以下兒童和年輕人癌症死亡的主要原因。 白血病沒有標準的分期系統，白血病分為未經治療、緩解或復發。

BCR-ABL，又稱費城（Ph）染色體，是由22號染色體上的BCR基因和9號染色體上的ABL1基因相互易位形成的突變。 這種易位導致 BCR-ABL 融合基因產生融合蛋白（一種酪氨酸激□信號蛋白），該蛋白被組成型激活，導致不受控制的細胞分裂。

BCR-ABL 檢測包括 BCR-ABL 原位雜交 (ISH)、BCR-ABL 核酸擴增 (NAAT)、BCR-ABL 新一代定序 (NGS)、BCR-ABL 桑格定序和 BCR-ABL 包括焦磷酸測序和細胞遺傳學測試。

本報告深入探討了全球 BCR-ABL 測試市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響、區域和國家趨勢等。

目錄

目前BCR-ABL市場測試及競爭狀況

• 對主要產業趨勢的見解
• BCR-ABL 按細分市場測試總市場收入以及 2015 年至 2033 年的市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• BCR-ABL測試市場的SWOT分析
• BCR-ABL 測試市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BCR-ABL Tests market for the year 2020 and beyond. Leukemia is a heterogeneous group of cancers that affects the blood and bone marrow. Two common subtypes are lymphocytic leukemia's and myeloid leukemia's, which derive from lymphoid cells and myeloid cells, respectively. Leukemia can progress rapidly (acute), or slowly (chronic), and is the primary cause of deaths from cancer in children and young adults under the age of 20 years. There is no standard staging system for leukemia; the disease as described as untreated, in remission, or recurrent.

BCR-ABL is a mutation, also known as the Philadelphia (Ph) chromosome, which is formed by a reciprocal chromosomal translocation of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. This translocation results in a BCR-ABL fusion gene and production of a fusion protein - a tyrosine kinase signaling protein this is constitutively active, causing cells to divide uncontrollably.

The BCR-ABL tests include BCR-ABL In Situ Hybridization (ISH), BCR-ABL Nucleic Acid Amplification (NAATs), BCR-ABL Next Generation Sequencing (NGS), BCR-ABL Sanger Sequencing, BCR-ABL Pyrosequencing and Cytogenetics tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed BCR-ABL tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total BCR-ABL tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BCR-ABL Tests market.
• Competitive dynamics insights and trends provided for BCR-ABL Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Sysmex Corp, Bio-Techne Corp, Danaher Corp, Bio-Rad Laboratories Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Takara Bio Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BCR-ABL Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to-

• Understand the impact of COVID-19 on BCR-ABL Tests market.
• Develop and design you're in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving BCR-ABL Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BCR-ABL Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific BCR-ABL Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable